BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  American Journal of Clinical Pathology

• Publication date

  2005-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1309/YQBR9C05RU4DD3RNPMID 15842051
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutations of BRAF and RAS are rare events in germ cell tumours

  2005cited by this paper
• High frequency of BRAF mutations in nevi

  2003cited by this paper
• BRAF and KRAS mutations in stomach cancer

  2003cited by this paper
• BRAF mutations in papillary carcinomas of the thyroid

  2003cited by this paper
• Mutations of the BRAF gene in squamous cell carcinoma of the head and neck

  2003cited by this paper
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper
• BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC

  2003cited by this paper
• Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.

  2002cited by this paper
• BRAF and RAS mutations in human lung cancer and melanoma.

  2002cited by this paper
• Missense mutations of the BRAF gene in human lung adenocarcinoma.

  2002cited by this paper
• Activation of ERK, Controlled by Rac1 and Cdc42 via Akt, Is Required for Anoikis

  2002cited by this paper
• A core–BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes

  2002cited by this paper
• Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.

  2001cited by this paper
• Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours.

  2001cited by this paper
• The Raf/MEK/ERK pathway: new concepts of activation

  2001cited by this paper
• Histological Typing of Endocrine Tumours

  2000cited by this paper
• Isotype-specific functions of Raf kinases.

  1999cited by this paper
• Morphological-Histochemical study of intestinal carcinoids and K-ras mutation analysis in appendiceal carcinoids

  1999cited by this paper
• Analysis of K-ras, N-ras, H-ras, and p53 in lung neuroendocrine neoplasms.

  1999cited by this paper
• Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors

  1998cited by this paper
• Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin.

  1995cited by this paper

• Gastrointestinal and Pancreatic Neuroendocrine Tumors: Pathological Classification, Diagnosis, Treatment, and Challenges

  2025cites this paper
• Papillary thyroid carcinoma and strumal carcinoid transformations of a mature cystic teratoma with NRAS codon 61 mutation: A case report.

  2025cites this paper
• An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects

  2024cites this paper
• Malignant insulinoma: Can we predict the long-term outcomes?

  2022cites this paper
• Agminated melanocytic nevi as a rare variant of melanocytic nevus: Report of two cases

  2020cites this paper
• From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

  2020influential citation
• Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition

  2019cites this paper
• Chapter 2 Inherited and Somatic Genetics of Pancreatic Neuroendocrine Tumors

  2018cites this paper
• BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma

  2018cites this paper
• Neuroendocrine neoplasms of rectum: A management update.

  2018cites this paper
• Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors

  2016cites this paper
• Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?

  2015cites this paper
• Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status.

  2015cites this paper
• Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology

  2015cites this paper
• Neuroendocrine Tumors of the Pancreas

  2015cites this paper
• GNA15 expression in small intestinal neuroendocrine neoplasia: functional and signalling pathway analyses.

  2015cites this paper
• Inherited and Somatic Genetics of Pancreatic Neuroendocrine Tumors

  2015cites this paper
• VIPoma and PPoma

  2015cites this paper
• Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors

  2014influential citation
• RAF signaling in neuroendocrine neoplasms: from bench to bedside.

  2014cites this paper
• PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms

  2014influential citation
• Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1

  2014cites this paper
• A systematic review of bevacizumab efficacy in breast cancer.

  2014cites this paper
• EGFR, KRAS, BRAF-mutations and microsatellite instability are absent in goblet cell carcinoids of the appendix.

  2014cites this paper
• Cancer Therapy : Preclinical Cotargeting the PI 3 K and RAS Pathways for the Treatment of Neuroendocrine Tumors

  2014influential citation
• May 09, 2020 Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1,

  2014cites this paper
• Down-regulation of miR-129-5p and the let-7 family in neuroendocrine tumors and metastases leads to up-regulation of their targets Egr1, and

  2014cites this paper
• Down-regulation of miR-129-5p and the let-7 family in neuroendocrine tumors and metastases leads to up-regulation of their targets Egr1, and Bach1

  2014cites this paper
• Pancreatic Cancer Genomes: Toward Molecular Subtyping and Novel Approaches to Diagnosis and Therapy

  2013cites this paper
• The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation

  2013cites this paper
• EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets

  2012cites this paper
• Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.

  2012cites this paper
• Molecular pathology and genetics of pancreatic endocrine tumours.

  2012cites this paper
• MSH2 and CXCR4 involvement in malignant VIPoma

  2012cites this paper
• Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors.

  2011cites this paper
• Current treatment options for neuroendocrine tumors.

  2011cites this paper
• The biological hallmarks of ileal carcinoids

  2011cites this paper
• New medical strategies for midgut carcinoids.

  2010cites this paper
• Gastroenteropankreatische neuroendokrine Tumoren: Molekulargenetische Charakteristika

  2010cites this paper
• 7 Molecular Pathology of Pancreatic Endocrine Tumors

  2010cites this paper
• New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.

  2010cites this paper
• Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors

  2009cites this paper
• Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors)

  2009cites this paper
• Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors).

  2009cites this paper
• Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors

  2008cites this paper
• Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

  2008cites this paper
• Histopathological Features of Patients with Chronic Pancreatitis due to Mutations in the PRSS1 Gene: Evaluation of BRAF and KRAS2 Mutations

  2008cites this paper
• Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor–β1‐mediated regulatory abnormalities including up‐regulation of C‐Myc and MTA1

  2007cites this paper
• Molecular alterations during insulinoma tumorigenesis.

  2007cites this paper
• Molecular profiles of gastroenteropancreatic endocrine tumors

  2007cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 264 Tumour Biological Factors Characterizing Metastasizing Serotonin-producing Ileocaecal Carcinoids

  2007cites this paper
• Rap1/B-Raf Signaling Is Activated in Neuroendocrine Tumors of the Digestive Tract and Raf Kinase Inhibition Constitutes a Putative Therapeutic Target

  2007cites this paper
• Molecular alterations during insulinoma tumorigenesis.

  2007cites this paper
• Co-targeting the Pi3k and Ras Pathways for the Treatment of Neuroendocrine Tumors Department of Biostatistics And

  year unknowncites this paper